The Food and Drug Administration has approved Eli Lilly weight loss pill Foundayo, a once-daily obesity pill from Eli Lilly, offering patients a non-injectable option that may improve convenience but still faces cost and insurance barriers.
FDA Fast-Tracks New Obesity Pill Approval
The FDA has approved Eli Lilly weight loss pill Foundayo, the second GLP-1 pill for obesity, following a rapid 50-day review under a fast-track program for priority drugs. The decision marks one of the quickest approvals for a new drug class since 2002.
The pill will compete with a similar oral treatment from Novo Nordisk, the maker of Wegovy, which received FDA approval in December. Both treatments expand options beyond injectable weight-loss drugs.
Foundayo introduces a different active ingredient, Orforglipron, a small-molecule compound designed to mimic GLP-1 hormones. Unlike peptide-based drugs, it is easier for the body to absorb in pill form.
“We’ve created a small molecule chemical which gets into your body very well,” said Daniel Skovronsky, Eli Lilly’s chief scientific and product officer. “It can mimic the effects of the peptide and can be taken more conveniently.”
Convenience May Shape Patient Choice
Unlike Wegovy’s pill, which must be taken on an empty stomach with a 30-minute fasting period, Eli Lilly weight loss pill Foundayo can be taken at any time without food or water restrictions. Experts say that flexibility may improve adherence.
Clinical trial data reviewed by the FDA showed patients taking the highest dose of Foundayo for 72 weeks lost an average of 27.3 pounds, or 12.4% of body weight. Those on a placebo lost about 2.2 pounds, or 0.9%.
Common side effects included nausea, constipation, and diarrhea. While the drug showed strong results, it has not been directly compared with competing pills in head-to-head trials.
Novo Nordisk pushed back on claims of superiority. “Not all GLP-1s are the same,” said Jamey Millar, the company’s U.S. operations executive vice president. “Any reports claiming Orforglipron is more effective… are inaccurate and misleading.”
Dr. Catherine Varney, obesity medicine director at UVA Health, said real-world outcomes may differ. She noted that ease of use could give Foundayo an advantage for patients managing complex treatment routines.
“That’s where one is going to have a little bit more of an advantage,” Varney said. “So… to be determined.”
Cost and Coverage Remain Key Barriers
Despite new treatment options, affordability continues to limit access. Eli Lilly weight loss pill Foundayo starting price is about $149 per month for patients paying without insurance, compared with $299 for Lilly’s injectable alternative.
The company has not yet released a full list price, which typically determines insurance coverage and copay levels. Eli Lilly said patients with commercial insurance may pay as little as $25 per month with savings programs, while Medicare patients could pay around $50 starting in July.
Varney said cost, not fear of injections, is the biggest barrier for most patients. “Not once has needle phobia been an issue,” she said, noting that affordability often drives treatment decisions.
Lilly expects Eli Lilly weight loss pill Foundayo to be available in pharmacies within weeks and says it has sufficient supply to meet demand. The company anticipates the pill will appeal especially to patients hesitant to begin treatment with injections.
“I think ideally this medicine will be for people who haven’t tried a weight-loss drug yet,” Skovronsky said.
Visit Healthcare 360 Magazine For The Most Recent Information.
